Therefore, it is essential to reveal the underlying molecular basis for efficiently discriminating between sensitive and resistant cellular models in order to identify those T-ALL/LBL neoplasms that may become potential candidates for treatment with pan-PIM inhibitors. This evidence concerns the gene PIM1 and neoplasm.